Bristol-Myers Squibb announced positive results for the CAR-T therapy lisocabtagene maraleucel (liso-cel) in three studies at the American Society of Hematology Annual Meeting.

CTI BioPharma Corp.’s treatment for a type of blood cancer did not meet the main goal of a late-stage trial, sending the company’s shares down 17 percent.